Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron Once Daily in Peripheral Artery Disease (J2A-MC-GZPR)
jRCT2031250570Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in arteriosclerosis obliterans comparing Orforglipron with Placebo (2 arms). Primary endpoint: Percent Change from Baseline in Maximum Walking Distance. Started Mar 2026; status: recruiting.
02
Drugs
orforglipron
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on jRCT2031250570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250570.